Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522742 · ClinicalTrials.gov registry record
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 29
- Enrollment target
NCT01522742: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT01522742 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522742 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to psoriasis patients with or without arthritis by their treating clinicians) will decrease cardiovascular inflammation.
Primary Outcome
Degree of aortic/coronary atherosclerotic plaque inflammation assessed via cardiac FDG-PET as target to background ratio (TBR) of the standardized uptake value (SUV).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-01 |
Why NCT01522742 stopped before completion
NCT01522742 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01522742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01522742 about?
NCT01522742 is a clinical study titled "Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study". The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to psoriasis patients with or without arthritis by their treating clinicians) wi...
What is the current status of trial NCT01522742?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2012-02. Estimated completion is 2016-01.
Who is sponsoring clinical trial NCT01522742?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia